Monte Rosa Therapeutics AG

https://www.monterosatx.com

	Start	2018-01-01 established
	Group	Monte Rosa Therapeutics (Group)
	Industry	protein degradation drug
	Industry 2	protein degradation technology
	Person	Warmuth, Markus (Monte Rosa Therapeutics 202009 CEO + Venture Partner at Versant Ventures before Eisai/H3 Biomedicine)

	Region	Basel BS
	Country	Switzerland
	Street	36 Aeschenvorstadt Labs at Technologiepark, Hochbergerstr. 60C, 4057 Basel
	City	4051 Basel
		Address record changed: 2020-12-02

Basic data	Employees	n. a.


		Record changed: 2023-07-10

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Monte Rosa Therapeutics (Group)

[1] Monte Rosa Therapeutics, Inc.. (6/23/21). "Press Release: Monte Rosa Therapeutics Announces Pricing of Initial Public Offering". Boston, MA....
[2] Monte Rosa Therapeutics. (3/12/21). "Press Release: Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform". Boston, MA....
[3] Monte Rosa Therapeutics. (9/24/20). "Press Release: Monte Rosa Therapeutics Announces $96 Million Series B Financing to Advance Small Molecule-based Protein Degradation Platform". Boston, MA....
[4] Monte Rosa Therapeutics. (5/26/20). "Press Release: Monte Rosa Therapeutics Discloses $32.5 Million Financing. Launched from Versant’s Ridgeline Discovery Engine". Boston, MA & Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]